Biogen | BIIB - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.53B 4.47B 2026-03
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Bayer EUR 35.3B 2.39B 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Incyte USD 5.48B 460.36M 2026-03
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.16B 789M 2026-03
Sanofi EUR 30.95B 8.99B 2025-12
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03